You are herePharma News

Pharma News


No evidence of accelerated Ebola Virus Evolution in West Africa: NIH

The Ebola virus circulating in humans in West Africa is undergoing relatively few mutations, none of which suggest that it is becoming more severe or transmissible, according to a National Institutes of Health study in Science. The study compares virus sequencing data from samples taken from patients in Guinea (March 2014), Sierra Leone (June 2014) and Mali (November 2014).


PAREXEL announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services-

PAREXEL International Corporation, a global clinical research organization, announced today that the Company has signed a definitive agreement to acquire all of the business assets of privately-owned Quantum Solutions India (QSI), a leading provider of specialized pharmacovigilance services, based in Chandigarh, India.  Pharmacovigilance refers to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products.  The acquisition is expected to close in early April of 2015, subject to the satisfaction of closing conditions.


Novo Nordisk to launch Novoeight® in the United States for People With Hemophilia A

Novo Nordisk today announced the company will launch Novoeight® (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A. Novoeight® offers purity, reliability, and enhanced portability, with the highest storage temperature for the longest period of time compared with other marketed recombinant Factor VIII products—up to 86 degrees F for 12 months. It can be kept at that temperature for up to 4 hours after reconstitution, giving it the longest postreconstitution storage time. Novoeight® offers purity through a 5-step purification process. It was shown to be safe and effective in clinical trials with zero inhibitors confirmed in 213 previously treated patients with hemophilia A. Novo Nordisk plans to make Novoeight® available by mid-April 2015.


Tumor Ablation Market Worth $462.0 Million by 2019

According to a new market research report "Tumor Ablation Market by Procedure Volume, Technology (RF, Microwave, Cryoablation, Others), Department (Interventional Radiology, Surgery, Oncology), Application (Liver Cancer, Lung Cancer, Kidney Cancer, Bone Metastasis) - Global Forecasts to 2019", published by MarketsandMarkets, the Tumor Ablation Market is expected to reach around $462.0 Million growing at a CAGR of 11.50% by 2019.


Sun Pharma compeletes merger deal with Ranbaxy

Sun Pharmaceutical Industries Ltd.  begins the integration of Ranbaxy’s business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth.


Dr. Reddy’s starts new Center of Excellence for Fully Integrated Formulation Development Services

Dr. Reddy’s Custom Pharmaceutical Services (CPS) division has expanded its existing custom service facilities with a new formulation development laboratory in Miyapur, Hyderabad, India. Bringing together the existing API development team and the formulation teams at one location will accelerate project timelines, reduce costs and simplify licensing processes for CPS’ pharma customers.


First WHO Collaborating Centre in South East Asia Region at India

World Health Organization (WHO) Country office for India in collaboration with the Ministry of Health and Family Welfare, Government of India and National Health Systems Resource Centre (NHSRC), formally announced the commencement of National Health Systems Resource Centre (NHSRC), as the WHO Collaborating Centre for Priority Medical Devices and Health Technology Policy.


Novartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx™ (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. Results were presented for the first time in a late-breaking session at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco. Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved to treat adult moderate-to-severe plaque psoriasis patients.


'Hiding Place' of HIV in Cells Discovered

Scientists have discovered the hiding place of HIV in cells, an advance that may lead to new therapies to combat the deadly virus. Researchers at the International Center for Genetic Engineering and Biotechnology (ICGEB) in Italy have photographed the structure of nucleic lymphocytes with a high-resolution microscopy technique to discover the "hiding place" of HIV.


First-ever human population adaptation to arsenic identified

Scientists have identified the first-ever evidence of a human population uniquely adapted to tolerate the toxic chemical arsenic in the Andes Mountains of Argentina. A Swedish research team led by Karolinska Institutet and Uppsala University professor Karin Broberg, performed a genome wide survey from a group of 124 Andean women screened for the ability to metabolise arsenic (measured by levels in the urine).